Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
暂无分享,去创建一个
E. Hellström-Lindberg | H. Kreipe | A. Giagounidis | B. Schlegelberger | G. Büsche | G. Göhring | C. Aul | M. Zimmermann | M. Zimmermann